BioXcel Therapeutics, Inc. short interest in 2023
In 2023, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 8.28% of shares outstanding on 13 Jan 2023 to 10.13% on 29 Dec 2023, a change of +1.85 percentage points. The year's high was 29.90% on 14 Jul 2023 and its low 8.28% on 13 Jan 2023, averaging 14.51% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.60 days on 28 Apr 2023. Full history: BioXcel Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 8.28% (13 Jan 2023)
- End of year
- 10.13% (29 Dec 2023)
- Change
- +1.85 pp
- High
- 29.90% (14 Jul 2023)
- Low
- 8.28% (13 Jan 2023)
- Average
- 14.51%
- Highest days to cover
- 9.60 (28 Apr 2023)
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 8.28% | 6.08 | |
| 31 Jan 2023 | 8.76% | 7.07 | |
| 15 Feb 2023 | 9.19% | 5.80 | |
| 28 Feb 2023 | 10.03% | 7.61 | |
| 15 Mar 2023 | 10.25% | 5.23 | |
| 31 Mar 2023 | 12.40% | 4.62 | |
| 14 Apr 2023 | 12.87% | 9.18 | |
| 28 Apr 2023 | 12.19% | 9.60 | |
| 15 May 2023 | 11.53% | 6.58 | |
| 31 May 2023 | 12.84% | 5.12 | |
| 15 Jun 2023 | 15.75% | 8.89 | |
| 30 Jun 2023 | 17.68% | 1.24 | |
| 14 Jul 2023 | 29.90% | 1.00 | |
| 31 Jul 2023 | 24.27% | 5.96 | |
| 15 Aug 2023 | 23.06% | 2.99 | |
| 31 Aug 2023 | 15.02% | 4.76 | |
| 15 Sep 2023 | 16.22% | 3.87 | |
| 29 Sep 2023 | 12.22% | 5.69 | |
| 13 Oct 2023 | 17.00% | 1.99 | |
| 31 Oct 2023 | 19.85% | 1.00 | |
| 15 Nov 2023 | 17.34% | 1.23 | |
| 30 Nov 2023 | 11.75% | 3.28 | |
| 15 Dec 2023 | 9.81% | 4.28 | |
| 29 Dec 2023 | 10.13% | 4.57 |
See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.